glp-1 blindness A potentially blinding condition is a very rare side effect of the receptor agonist semaglutide (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded. https://www.medpagetoday.com/ophthalmology/generalophthalmology/115938?trw=no kentucky glp-1 stomach paralysis law

The algorithm is given in Alg

These interactions may not only affect how well the body absorbs B12 but also how it metabolises and utilises the vitamin, potentially leading to an increase in discomfort post-injection

Most people then feel either neutral or noticeably better as the deficiency corrects

trials flagged severe abdominal pain for discontinuation and evaluation Gallbladder problems rapid weight loss increases gallstone risk Thyroid C-cell tumors the FDA black box warning for the approved semaglutide products cites contraindication in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2) Most GI side effects improve within 4-8 weeks and are reduced by slower titration mg to Units Conversion On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL)